Lung & Bronchus
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Planchard D, et al
A long-term safety analysis of the phase 3 FLAURA2 trial demonstrates that grade ≥3 adverse event onset frequency progressively declined across successive treatment periods in patients receiving osimertinib plus platinum-pemetrexed for EGFR-mutated advanced NSCLC — from 43% during the induction phas…
Source →Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.
Chen X, et al
A comprehensive review published in Biochimica et Biophysica Acta synthesizes the rapidly evolving landscape of antibody-based therapeutics designed to overcome acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). The review covers monoclonal antibodie…
Source →Single-cell and spatial transcriptomic technologies for lung cancer tumor microenvironment analysis.
Braicu C, et al
A new narrative review published in Biochimica et Biophysica Acta – Reviews on Cancer concludes that spatially structured cellular ecosystems within the lung cancer tumor microenvironment, rather than individual cell types considered in isolation, are the primary determinants of therapeutic response…
Source →The shifting burden of tracheal, bronchus and lung cancer in ageing Asia: structural drivers and projections to 2050.
Zhu L, et al
A major epidemiological study using Global Burden of Disease 2023 data found that tracheal, bronchus, and lung (TBL) cancer cases among Asian adults aged 60 and older more than tripled between 1990 and 2023, rising from 334,563 to 1,102,794 incident cases, with DALYs increasing from 7.3 million to 1…
Source →Guillain-Barré Syndrome Following the Administration of Tarlatamab in Extensive-stage Small Cell Lung Cancer: A Case Report with Pathological Confirmation.
Tokunaga Y, et al
Researchers report the first pathologically confirmed case of Guillain-Barré syndrome (GBS) associated with tarlatamab, a bispecific T-cell engager targeting DLL3 and CD3, in a patient receiving treatment for extensive-stage small cell lung cancer (SCLC). Following the initial dose of tarlatamab, th…
Source →Thioredoxin reductase-1 facilitates cellular plasticity and stemness mediated by TGF-β1 in non-small cell lung cancer.
Lang Y, et al
Researchers have identified thioredoxin reductase-1 (TXNRD1), a redox enzyme expressed approximately 2-fold higher in advanced-stage non-small cell lung cancer (NSCLC), as a key driver of cancer cell plasticity and metastasis through an autocrine TGF-β1 signaling loop. Using CRISPR/Cas9 and siRNA kn…
Source →Topologically distinct intratumoral heterogeneity scores for predicting high-risk pathological grades in invasive lung adenocarcinoma: A multicenter study across four institutions.
Lin S, et al
A multicenter study of 1,051 patients with invasive lung adenocarcinoma (IAC) demonstrated that a stacking ensemble machine learning classifier combining topologically distinct intratumoral heterogeneity (ITH) scores derived from CT images with clinicoradiological features achieved an area under the…
Source →Lung Cancer Screening: Beyond Pulmonary Nodules.
Singh A, et al
A practical framework published in Radiographics reveals that low-dose CT scans already used for lung cancer screening can simultaneously detect a wide range of serious incidental conditions—including emphysema, coronary artery calcification, thoracic aortic aneurysm, interstitial lung disease, low …
Source →Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.
Prudente V, et al
A multicohort study of 1,107 non-small cell lung cancer (NSCLC) patients has found that incidental radiation exposure to the thymus during radiotherapy is independently associated with significantly higher risks of distant metastasis and death, with each 1 Gy increase in Mean Thymic Dose linked to a…
Source →First-line therapy and maintenance outcomes in Chinese patients with marginal zone lymphoma: a multicenter retrospective analysis with prognostic implications for chemotherapy decision-making.
Qiu Y, et al
A multicenter retrospective study of 171 newly diagnosed marginal zone lymphoma (MZL) patients in Fujian Province, China found that maintenance therapy was associated with a significant overall survival benefit, with 5-year OS reaching 100% in patients who received maintenance versus 87.5% in those …
Source →Indwelling pleural catheter enabling safe air travel in malignant pleural effusion with pneumothorax ex vacuo.
Lachal F, et al
A man with pleural mesothelioma and malignant pleural effusion complicated by pneumothorax ex vacuo was able to safely undertake a domestic flight after a specific in-flight management protocol was developed around his indwelling pleural catheter (IPC). Pneumothorax of any cause is typically a contr…
Source →Silk Sericin/Fibroin Composite Drug Delivery Systems for Lung Cancer: Mechanistic Rationale, Potential Functional Complementarity, and Future Perspectives.
Cho H, et al
A new review evaluates silk fibroin (SF) and silk sericin (SS) composite biomaterials as drug delivery platforms for lung cancer, concluding that while selected SS/SF composites show promising combinations of pulmonary accumulation, environment-responsive drug release, prolonged local retention, and…
Source →Corrigendum to "EML4-ALK fusion in small cell lung cancer: clinical and molecular insights from a rare case" [Lung Cancer 202 (2025) 108497].
Jaber G, et al
This publication is a corrigendum — a formal correction notice — issued for a previously published case report titled 'EML4-ALK fusion in small cell lung cancer: clinical and molecular insights from a rare case' (Lung Cancer, 2025, 108497). The original article described a rare instance of EML4-ALK …
Source →Retraction notice to "MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway" [Cellular Signalling 73 (2020) 109675].
Yang F, et al
The journal Cellular Signalling has issued a formal retraction of the 2020 article titled "MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway" (Cellular Signalling 73 (2020) 109675), meaning the study's findings are no longe…
Source →Spatial mapping of cardiac dose-survival associations in oesophageal radiotherapy.
Marchant T, et al
A study of 452 patients treated with curative-intent radiotherapy for oesophageal cancer identified a spatially localized cardiac region where higher radiation dose was significantly associated with worse 12-month survival, with a maximum Cardiac Avoidance Area (CAA) dose threshold of 43.5 Gy produc…
Source →